Linda A Schuler

List of Publications by Year
in descending order

25 papers	1,454 citations	471509 17 h-index	610901 24 g-index
26 all docs	26 docs citations	26 times ranked	1465 citing authors

#	Article	IF	Citations
1	The Role of Prolactin in Mammary Carcinoma. Endocrine Reviews, 2003, 24, 1-27.	20.1	480
2	Prolactin induces ERÎ±-positive and ERÎ±-negative mammary cancer in transgenic mice. Oncogene, 2003, 22, 4664-4674.	5.9	165
3	Stiff Collagen Matrices Increase Tumorigenic Prolactin Signaling in Breast Cancer Cells. Journal of Biological Chemistry, 2013, 288, 12722-12732.	3.4	112
4	Elevated collagen-I augments tumor progressive signals, intravasation and metastasis of prolactin-induced estrogen receptor alpha positive mammary tumor cells. Breast Cancer Research, 2017, 19, 9.	5.0	104
5	PRL Modulates Cell Cycle Regulators in Mammary Tumor Epithelial Cells. Molecular Endocrinology, 2002, 16, 45-57.	3.7	83
6	Prolactin-induced mouse mammary carcinomas model estrogen resistant luminal breast cancer. Breast Cancer Research, 2011, 13, R11.	5.0	53
7	Dense Collagen-I Matrices Enhance Pro-Tumorigenic Estrogen-Prolactin Crosstalk in MCF-7 and T47D Breast Cancer Cells. PLoS ONE, 2015, 10, e0116891.	2.5	48
8	Src Family Kinases Accelerate Prolactin Receptor Internalization, Modulating Trafficking and Signaling in Breast Cancer Cells. Molecular Endocrinology, 2009, 23, 202-212.	3.7	43
9	Complex prolactin crosstalk in breast cancer: New therapeutic implications. Molecular and Cellular Endocrinology, 2009, 307, 1-7.	3.2	40
10	Prolactin Potentiates Transforming Growth Factor Î± Induction of Mammary Neoplasia in Transgenic Mice. American Journal of Pathology, 2006, 168, 1365-1374.	3.8	37
11	Transgenic Models to Study Actions of Prolactin in Mammary Neoplasia. Journal of Mammary Gland Biology and Neoplasia, 2008, 13, 29-40.	2.7	31
12	Dynamic interactions between the extracellular matrix and estrogen activity in progression of ER+ breast cancer. Oncogene, 2019, 38, 6913-6925.	5.9	31
13	High collagen density augments mTOR-dependent cancer stem cells in ERÎ±+ mammary carcinomas, and increases mTOR-independent lung metastases. Cancer Letters, 2018, 433, 1-9.	7.2	29
14	Ovarian hormones are not required for PRL-induced mammary tumorigenesis, but estrogen enhances neoplastic processes. Journal of Endocrinology, 2009, 203, 99-110.	2.6	24
15	Prolactin Activates ERÎ± in the Absence of Ligand in Female Mammary Development and Carcinogenesis in Vivo. Endocrinology, 2013, 154, 4483-4492.	2.8	23
16	Prolactin Alters the Mammary Epithelial Hierarchy, Increasing Progenitors and Facilitating Ovarian Steroid Action. Stem Cell Reports, 2017, 9, 1167-1179.	4.8	22
17	Antiestrogen Therapy Increases Plasticity and Cancer Stemness of Prolactin-Induced ERÎ±+ Mammary Carcinomas. Cancer Research, 2018, 78, 1672-1684.	0.9	21
18	Modeling Prolactin Actions in Breast Cancer In Vivo: Insights from the NRL-PRL Mouse. Advances in Experimental Medicine and Biology, 2015, 846, 201-220.	1.6	21

#	Article	IF	Citations
19	Prolactin signaling through focal adhesion complexes is amplified by stiff extracellular matrices in breast cancer cells. Oncotarget, 2016, 7, 48093-48106.	1.8	20
20	A Spontaneous Aggressive ERÎ±+ Mammary Tumor Model Is Driven by Kras Activation. Cell Reports, 2019, 28, 1526-1537.e4.	6.4	19
21	Prolactin: The Third Hormone in Breast Cancer. Frontiers in Endocrinology, 0, 13, .	3.5	15
22	17Î²-Estradiol and ICI182,780 Differentially Regulate STAT5 Isoforms in Female Mammary Epithelium, With Distinct Outcomes. Journal of the Endocrine Society, 2018, 2, 293-309.	0.2	9
23	Modeling chemical effects on breast cancer: the importance of the microenvironment in vitro. Integrative Biology (United Kingdom), 2020, 12, 21-33.	1.3	9
24	Prolactin synergizes with canonical Wnt signals to drive development of ER+ mammary tumors via activation of the Notch pathway. Cancer Letters, 2021, 503, 231-239.	7.2	8
25	Endogenous and Therapeutic Estrogens: Maestro Conductors of the Microenvironment of ER+ Breast Cancers. Cancers, 2021, 13, 3725.	3.7	7